Figure 4
From: Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14·TRAIL
Treatment with Fn14·TRAIL suppresses T-cell reactivity during various stages of experimental autoimmune encephalomyelitis (EAE) course. (A) T-cell proliferation in response to encephalitogenic peptide MOG35-55 was assessed upon termination of treatment (day 17 post-induction) and 5 days later (day 22). Animals received 200 μg/day for 7 days from day 10 post- EAE induction. (B – D) Fn14·TRAIL reduced production of Th1 and Th17 cytokines IFNγ and IL-17, with no change in production of Th2 cytokine IL-10. ( E-F) Fn14·TRAIL effects were determined on mRNA levels of the Th2 lineage-specific transcription factor (TF) GATA-3, with increased expression (E), and a reduction in Th17 TF RORγT (F). *P <0.05, **P <0.01